Novocure reports Q3 2026 results, raises 2026 guidance and announces Japan approval for Optune Pax

Novocure posted third‑quarter 2026 net revenue of $193.4 million, a 16% year‑over‑year increase, while recording a net loss of $10.4 million ($0.09 per share). Adjusted EBITDA reached $15.7 million. The company lifted its full‑year 2026 revenue outlook to $736 million‑$743 million and its adjusted EBITDA target to $24 million‑$34 million. In October, Japan’s health ministry approved Optune Pax for locally advanced pancreatic cancer, and Novocure announced a collaboration with Verastem Oncology on pancreatic‑cancer trials.

The company said the raised guidance reflects confidence in continued top‑line growth, but the quarter’s loss shows profitability is still a work‑in‑progress. The Japan approval of Optune Pax could add a new revenue stream, supporting future growth, as noted by the company.

  • 1Q3 2026 net revenue was $193.4 million, up 16% year‑over‑year.
  • 2Net loss for the quarter was $10.4 million, or $0.09 per share.
  • 3Adjusted EBITDA for the quarter was $15.7 million.
  • 4Full‑year 2026 net revenue guidance was raised to $736 million‑$743 million.
  • 5Adjusted EBITDA guidance for 2026 was set to $24 million‑$34 million.
  • 6Optune Pax received approval in Japan for locally advanced pancreatic cancer.

Sources